Clinical Trial to Evaluate the Efficacy and Safety of DP-R212

Alvogen Korea

Overview

The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Hypertension Hypercholesterolemia

Interventions

DP-R212DRUG

DP-R212 + C1-R212 placebo + C2-R212 placebo

C1-R212DRUG

DP-R212 placebo + C1-R212 + C2-R212 placebo

C2-R212DRUG

DP-R212 placebo + C1-R212 placebo + C2-R212

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Both man and woman who is over 19 years old * Hypertension patient with hypercholesterolemia Exclusion Criteria: * sSBP difference is ≥20mmHg or sDBP difference is ≥10mmHg * A history of cardiovascular disease * rhabdomyolysis, myopathy * Hypertension or hypercholesterolemia due to secondary causes * Uncontrolled diabetes * Evidence of hepatic or renal disease

Outcomes

Primary Outcomes

Percent change of LDL-Cholesterol

Time frame: 0, 8 weeks

Change of mean seated Systolic Blood Pressure

Time frame: 0, 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.